C
Carlos A. Guzmán
Researcher at University of Genoa
Publications - 281
Citations - 10481
Carlos A. Guzmán is an academic researcher from University of Genoa. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 54, co-authored 260 publications receiving 9506 citations. Previous affiliations of Carlos A. Guzmán include Hannover Medical School & Bill & Melinda Gates Foundation.
Papers
More filters
Journal ArticleDOI
Molecular analysis of the bvg-repressed urease of Bordetella bronchiseptica.
TL;DR: It is demonstrated that increasing the concentration of urea in the assay increased survival of the urease-positive but not ure enzyme-negative strains after 24 h, suggesting that Urease does have a role in intracellular survival.
Journal ArticleDOI
Pegylated Bisacycloxypropylcysteine, a Diacylated Lipopeptide Ligand of TLR6, Plays a Host-Protective Role against Experimental Leishmania major Infection
Surya Prakash Pandey,Himanshu Singh Chandel,Sunit Srivastava,Sathishkumar Selvaraj,Mukesh Kumar Jha,Divanshu Shukla,Thomas Ebensen,Carlos A. Guzmán,Bhaskar Saha +8 more
TL;DR: BPPcysMPEG, a novel diacylated lipopeptide ligand for TLR2–TLR6 heterodimer, induces IL-12-dependent, inducible NO synthase–dependent, T-reg–sensitive antileishmanial protection and the data reveal a novel dimerization partner-dependent duality inTLR2 function.
Journal ArticleDOI
Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection†
Nirupma Trehanpati,Robert Geffers,Sukriti,Syed Hissar,Peggy Riese,Tanja Toepfer,Jan Buer,Manoj Kumar,Carlos A. Guzmán,Shiv Kumar Sarin +9 more
TL;DR: The fingerprints enable clear discrimination between patients suffering from AVH‐B or CHB infection and support the hypothesis of suppressed CD4+ effector T cells favoring viral persistence in the chronic infection stage.
Book ChapterDOI
Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design.
Thomas Ebensen,Carlos A. Guzmán +1 more
TL;DR: The development of new adjuvants which are able to promote broad and sustained immune responses at systemic and mucosal levels and which are currently under preclinical or clinical development will be described in this chapter.
Journal ArticleDOI
Incidence of hemagglutination activity among pathogenic and non-pathogenic Bacteroides fragilis strains and role of capsule and pili in HA and adherence.
TL;DR: It was found that hemagglutinating strains are more frequently isolated from clinical specimens (55%) than from feces of healthy donors (20%).